Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
Endocr Res ; 47(1): 39-44, 2022 Feb.
Article in English | MEDLINE | ID: covidwho-1510751

ABSTRACT

BACKGROUND: Integrin αvß3 is a cell membrane structural protein whose extracellular domain contains a receptor for L-thyroxine (T4). The integrin is expressed in rapidly dividing cells and its internalization is prompted by T4. The protein binds viruses and we have raised the possibility elsewhere that action of free T4 (FT4)-when he latter is increased in the nonthyroidal illness syndrome (NTIS) known to complicate COVID-19 infecction-may enhance cellular uptke of SARS-CoV-2 and its receptor. OBJECTIVE: Because T4 also acts nongenomically via the integrin to promote platelet aggregation and angiogenesis, we suggest here that T4 may contribute to the coagulopathy and endothelial abnormalities that can develop in COVID-19 infections, particularly when the lung is primary affected. DISCUSSION AND CONCLUSIONS: Elevated FT4 has been described in the NTIS of COVID-19 patients and may be associated with increased illness severity, but the finding of FT4 elevation is inconsistent in the NTIS literature. Circulating 3,5',3'-triiodo-L-thyronine (reverse T3, rT3) are frequently elevated in NTIS. Thought to be biologically inactive, rT3in fact stimulates cancer cell proliferation via avb3 and also may increase actin polymerization. We propose here that rT3 in the NTIS complicating systemic COVIF-19 infection may support coagulation and disordered blood vessel formation via actin polymerization.


Subject(s)
COVID-19 , Humans , Integrin alphaVbeta3 , Male , SARS-CoV-2 , Thyroid Hormones , Thyroxine , Triiodothyronine
2.
Ann Endocrinol (Paris) ; 81(5): 507-510, 2020 Oct.
Article in English | MEDLINE | ID: covidwho-778380

ABSTRACT

The World Health Organization (WHO) declared the COVID-19 epidemic to be a global pandemic in March 2020. COVID-19 is an infection caused by SARS-CoV-2, a coronavirus that utilizes the angiotensin-2 converting enzyme to penetrate thyroid and pituitary cells, and may result in a "cytokine storm". Based on the pathophysiological involvement of the pituitary-thyroid axis, the current review discusses the diagnosis of abnormal thyroid function test, and the management of patients presenting with thyrotoxicosis, thyroid-associated orbitopathy and hypothyroidism in the context of SARS-CoV-2 infection.


Subject(s)
Betacoronavirus , Coronavirus Infections/complications , Pandemics , Pneumonia, Viral/complications , Thyroid Diseases/etiology , Angiotensin-Converting Enzyme 2 , Apoptosis , COVID-19 , Coronavirus Infections/drug therapy , Coronavirus Infections/physiopathology , Cytokine Release Syndrome/etiology , Cytokine Release Syndrome/physiopathology , Disease Susceptibility , Graves Ophthalmopathy/complications , Humans , Hydroxychloroquine/adverse effects , Hydroxychloroquine/therapeutic use , Hypothyroidism/blood , Hypothyroidism/etiology , Hypothyroidism/physiopathology , Interleukin-6/physiology , Peptidyl-Dipeptidase A/analysis , Pituitary Gland/physiopathology , Pneumonia, Viral/drug therapy , Pneumonia, Viral/physiopathology , Receptors, Virus/analysis , SARS-CoV-2 , Thyroid Diseases/blood , Thyroid Diseases/physiopathology , Thyroid Gland/chemistry , Thyroid Gland/pathology , Thyroid Gland/physiopathology , Thyroid Hormones/blood , Thyrotoxicosis/blood , Thyrotoxicosis/etiology , Thyrotoxicosis/physiopathology , Thyrotropin/blood , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL